• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Recent highlights on Omicron as a new SARS-COVID-19 variant: evolution, genetic mutation, and future perspectives.奥密克戎作为一种新型 SARS-COVID-19 变体的最新研究进展:进化、基因突变和未来展望。
J Drug Target. 2022 Jul;30(6):603-613. doi: 10.1080/1061186X.2022.2056187. Epub 2022 Mar 28.
2
Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile.关于关注的 SARS-CoV-2 奥密克戎变异株及其特殊突变特征的最新信息。
Microbiol Spectr. 2022 Apr 27;10(2):e0273221. doi: 10.1128/spectrum.02732-21. Epub 2022 Mar 30.
3
Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics.奥密克戎 SARS-CoV-2 新变体:全球流行情况以及生物学和临床特征。
Eur Rev Med Pharmacol Sci. 2021 Dec;25(24):8012-8018. doi: 10.26355/eurrev_202112_27652.
4
Comparison of SARS-Cov-2 omicron variant with the previously identified SARS-Cov-2 variants in Egypt, 2020-2022: insight into SARS-Cov-2 genome evolution and its impact on epidemiology, clinical picture, disease severity, and mortality.比较 2020-2022 年埃及出现的 SARS-CoV-2 奥密克戎变异株与之前鉴定的 SARS-CoV-2 变异株:对 SARS-CoV-2 基因组进化及其对流行病学、临床特征、疾病严重程度和死亡率影响的深入了解。
BMC Infect Dis. 2023 Aug 18;23(1):542. doi: 10.1186/s12879-023-08527-y.
5
Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8 T-Cell Epitopes Identified in COVID-19 Convalescent Individuals.在 COVID-19 康复个体中鉴定的与 SARS-CoV-2 的奥密克戎变异株相关的突变和 CD8 T 细胞表位之间最小交叉。
mBio. 2022 Apr 26;13(2):e0361721. doi: 10.1128/mbio.03617-21. Epub 2022 Mar 1.
6
SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021.SARS-CoV-2 B.1.1.529(奥密克戎)变异株-美国,2021 年 12 月 1 日-8 日。
MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1731-1734. doi: 10.15585/mmwr.mm7050e1.
7
Editorial: World Health Organization (WHO) Variants of Concern Lineages Under Monitoring (VOC-LUM) in Response to the Global Spread of Lineages and Sublineages of Omicron, or B.1.1.529, SARS-CoV-2.社论:世界卫生组织(WHO)变异关注谱系监测(VOC-LUM)以应对奥密克戎(或 B.1.1.529)SARS-CoV-2 谱系和亚谱系在全球范围内的传播
Med Sci Monit. 2022 Jul 1;28:e937676. doi: 10.12659/MSM.937676.
8
Mutational cascade of SARS-CoV-2 leading to evolution and emergence of omicron variant.SARS-CoV-2 突变级联导致奥密克戎变体的进化和出现。
Virus Res. 2022 Jul 2;315:198765. doi: 10.1016/j.virusres.2022.198765. Epub 2022 Mar 31.
9
VOC-alarm: mutation-based prediction of SARS-CoV-2 variants of concern.VOC-alarm:基于突变的 SARS-CoV-2 关注变异株预测。
Bioinformatics. 2022 Jul 11;38(14):3549-3556. doi: 10.1093/bioinformatics/btac370.
10
Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?奥密克戎:为何最新的 SARS-CoV-2 变体如此令人担忧?
J Virol. 2022 Mar 23;96(6):e0207721. doi: 10.1128/jvi.02077-21.

引用本文的文献

1
Recruitment for Voluntary Video and Mobile HIV Testing on Social Media Platforms During the COVID-19 Pandemic: Cross-Sectional Study.招募自愿者通过社交媒体平台进行视频和移动 HIV 检测在 COVID-19 大流行期间:横断面研究。
J Med Internet Res. 2024 Nov 28;26:e54420. doi: 10.2196/54420.
2
Could the New BA.2.75 Sub-Variant Cause the Emergence of a Global Epidemic of COVID-19? A Scoping Review.新型BA.2.75亚变体是否会引发全球新冠疫情?一项范围综述。
Infect Drug Resist. 2022 Oct 31;15:6317-6330. doi: 10.2147/IDR.S387551. eCollection 2022.
3
Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world.SARS-CoV-2 疫苗的快速开发:拯救世界的疫苗。
Front Immunol. 2022 Oct 3;13:961198. doi: 10.3389/fimmu.2022.961198. eCollection 2022.
4
In Silico Evaluation of CRISPR-Based Assays for Effective Detection of SARS-CoV-2.基于CRISPR的检测方法用于有效检测新型冠状病毒的计算机模拟评估
Pathogens. 2022 Aug 25;11(9):968. doi: 10.3390/pathogens11090968.
5
A comprehensive analysis of the mutational landscape of the newly emerging Omicron (B.1.1.529) variant and comparison of mutations with VOCs and VOIs.对新出现的奥密克戎(B.1.1.529)变体的突变情况进行全面分析,并与 VOCs 和 VOIs 的突变进行比较。
Geroscience. 2022 Oct;44(5):2393-2425. doi: 10.1007/s11357-022-00631-2. Epub 2022 Aug 22.

本文引用的文献

1
Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.奥密克戎新冠病毒变体:新冠疫情的新篇章。
Lancet. 2021 Dec 11;398(10317):2126-2128. doi: 10.1016/S0140-6736(21)02758-6. Epub 2021 Dec 3.
2
Drug repurposing strategies and key challenges for COVID-19 management.药物重定位策略和管理 COVID-19 的关键挑战。
J Drug Target. 2022 Apr;30(4):413-429. doi: 10.1080/1061186X.2021.2013852. Epub 2021 Dec 9.
3
SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India.印度马哈拉施特拉邦第二波新冠疫情中出现的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白突变,L452R、T478K、E484Q和P681R
Microorganisms. 2021 Jul 20;9(7):1542. doi: 10.3390/microorganisms9071542.
4
B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies.B.1.526 型 SARS-CoV-2 变异株在纽约市被疫苗诱导和治疗性单克隆抗体中和。
mBio. 2021 Aug 31;12(4):e0138621. doi: 10.1128/mBio.01386-21. Epub 2021 Jul 27.
5
A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics.新型冠状病毒病病毒学、疫苗、变异株和治疗方法的全面综述。
Curr Med Sci. 2021 Dec;41(6):1037-1051. doi: 10.1007/s11596-021-2395-1. Epub 2021 Jul 9.
6
Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention.了解 ACE-2 受体在 COVID-19 疾病发病机制中的作用:一种潜在的治疗干预方法。
Pharmacol Rep. 2021 Dec;73(6):1539-1550. doi: 10.1007/s43440-021-00303-6. Epub 2021 Jun 27.
7
SARS-CoV-2 variants, spike mutations and immune escape.SARS-CoV-2 变体、刺突突变和免疫逃逸。
Nat Rev Microbiol. 2021 Jul;19(7):409-424. doi: 10.1038/s41579-021-00573-0. Epub 2021 Jun 1.
8
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.NVX-CoV2373 新冠疫苗对 B.1.351 变异株的有效性。
N Engl J Med. 2021 May 20;384(20):1899-1909. doi: 10.1056/NEJMoa2103055. Epub 2021 May 5.
9
Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016.逃避单克隆抗体LY-CoV555及其与LY-CoV016的鸡尾酒疗法的SARS-CoV-2受体结合域突变的完整图谱。
Cell Rep Med. 2021 Apr 20;2(4):100255. doi: 10.1016/j.xcrm.2021.100255. Epub 2021 Apr 5.
10
Symptomatic reinfection of SARS-CoV-2 with spike protein variant N440K associated with immune escape.出现症状的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)再感染,与刺突蛋白变体N440K相关,伴有免疫逃逸。
J Med Virol. 2021 Jul;93(7):4163-4165. doi: 10.1002/jmv.26997. Epub 2021 Apr 13.

奥密克戎作为一种新型 SARS-COVID-19 变体的最新研究进展:进化、基因突变和未来展望。

Recent highlights on Omicron as a new SARS-COVID-19 variant: evolution, genetic mutation, and future perspectives.

机构信息

Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research-Raebareli, Lucknow, India.

Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia.

出版信息

J Drug Target. 2022 Jul;30(6):603-613. doi: 10.1080/1061186X.2022.2056187. Epub 2022 Mar 28.

DOI:10.1080/1061186X.2022.2056187
PMID:35311601
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9115780/
Abstract

COVID-19 has affected the lives of billions of people and is a causative agent for millions of deaths. After 23 months of the first reported case of COVID-19, on 25th November 2020, a new SARS-COVID-19 variant, i.e. Omicron was reported with a WHO tagline of VoC that trembled the world with its infectivity rate. This fifth VoC raised the concern about neutralising ability and adequate control of SARS-COVID-19 infection due to mass vaccination drive (nearly more than 4.7 billion individuals got vaccinated globally till December 2021). However, the present scenario of VoCs highlights the importance of vaccination and public health measures that need to be followed strictly to prevent the fatality from Omicron. The world still needs to overcome the hesitancy that poses a major barrier to the implementation of vaccination. This review highlights the SARS-COVID-19 situation and discusses in detail the mutational events that occurred at a cellular level in different variants over time. This article is dedicated to the scientific findings reported during the recent outbreak of 2019-2022 and describes their symptoms, disease, spread, treatment, and preventive action advised. The article also focuses on the treatment options available for Covid-19 and the update of Omicron by expert agencies.

摘要

COVID-19 已经影响了数十亿人的生活,是数百万人死亡的原因。在首例 COVID-19 报告 23 个月后,即 2020 年 11 月 25 日,一种新的 SARS-COVID-19 变体,即奥密克戎被报告,世界卫生组织的一个标签是“VOC”,其传染性让世界震惊。这种第五个 VOC 引起了人们对中和能力和 SARS-COVID-19 感染的充分控制的关注,因为大规模的疫苗接种运动(截至 2021 年 12 月,全球已有近 47 亿人接种疫苗)。然而,目前 VOC 的情况突出了接种疫苗和公共卫生措施的重要性,需要严格遵守这些措施,以防止奥密克戎的致命性。世界仍需克服实施疫苗接种所面临的犹豫,这是实施疫苗接种的主要障碍。这篇综述强调了 SARS-COVID-19 的情况,并详细讨论了不同变体在细胞水平上随时间发生的突变事件。本文致力于报道最近 2019-2022 年爆发期间的科学发现,并描述了它们的症状、疾病、传播、治疗和建议的预防措施。文章还重点介绍了针对新冠病毒的治疗选择和专家机构对奥密克戎的更新。